| Entry |
|
|---|
| Name |
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN);
Adalimumab-adaz;
Adalimumab-adbm;
Adalimumab-afzb;
Adalimumab-atto;
Adalimumab-bwwd;
Adalimumab-fkjp;
Humira (TN);
Abrilada (TN);
Amjevita (TN);
Cyltezo (TN);
Hadlima (TN);
Hyrimoz (TN) |
|---|
| Product |
ABRILADA (Pfizer Laboratories Div Pfizer), ADALIMUMAB (Golden State Medical Supply), ADALIMUMAB (Mylan Specialty L.P.), ADALIMUMAB (Sandoz), ADALIMUMAB-ADBM (Boehringer Ingelheim Pharmaceuticals), AMJEVITA (A-S Medication Solutions), AMJEVITA (A-S Medication Solutions), AMJEVITA (Amgen USA), AMJEVITA (Amgen), CYLTEZO (Boehringer Ingelheim Pharmaceuticals), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (Organon LLC), HULIO (Mylan Specialty L.P.), HUMIRA (A-S Medication Solutions), HUMIRA (AbbVie), HYRIMOZ (Cordavis Limited), HYRIMOZ (Sandoz), IDACIO (Fresenius Kabi USA), YUFLYMA (CELLTRION USA), YUSIMRY (Coherus BioSciences) |
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody |
|---|
| Disease |
Rheumatoid arthritis [DS: H00630] Juvenile idiopathic arthritis [DS: H01672] Psoriatic arthritis [DS: H01507] Ankylosing spondylitis [DS: H01674] Adult Crohn's disease [DS: H00286] Pediatric Crohn's disease [DS: H00286] Ulcerative colitis [DS: H01466] Plaque psoriasis [DS: H01656] Hidradenitis suppurativa [DS: H00681] |
|---|
| Type |
Monoclonal antibody |
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04612 | Antigen processing and presentation |
| hsa04650 | Natural killer cell mediated cytotoxicity |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB04 Adalimumab
D02597 Adalimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Adalimumab
D02597 Adalimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D02597 Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D02597 Adalimumab
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D02597 Adalimumab
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D02597 Adalimumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D02597 Adalimumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02597
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
